Acknowledgement
Supported by : National Cancer Center
References
- Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodinerefractory thyroid cancer. N Engl J Med 2015;372(7):621-30. https://doi.org/10.1056/NEJMoa1406470
- Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940):319-28. https://doi.org/10.1016/S0140-6736(14)60421-9
- Kawalec P, Malinowska-Lipien I, Brzostek T, Kozka M. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib. Expert Rev Anticancer Ther 2016;16(12):1303-9. https://doi.org/10.1080/14737140.2016.1247697
- Yi KH, Lee EK, Kang HC, Koh Y, Kim SW, Kim IJ, et al. 2016 Revised Korean Thyroid Association Management Guidelines for patients with thyroid nodules and thyroid cancer. Int J Thyroidol 2016;9(2):59-126. https://doi.org/10.11106/ijt.2016.9.2.59
- Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1-133. https://doi.org/10.1089/thy.2015.0020
- Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16(15):1473-82. https://doi.org/10.1016/S1470-2045(15)00290-9
- Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 2013;63(4):249-79. https://doi.org/10.3322/caac.21184
- Puzziello A, Rosato L, Innaro N, Orlando G, Avenia N, Perigli G, et al. Hypocalcemia following thyroid surgery: incidence and risk factors. A longitudinal multicenter study comprising 2,631 patients. Endocrine 2014;47(2):537-42. https://doi.org/10.1007/s12020-014-0209-y
- Seong JY, Lee CR, Kim MJ, Kim TH, Lee SG, Choi JB, et al. Risk factors of postoperative hypocalcemia after total thyroidectomy of papillary thyroid carcinoma patients. Korean J Endocr Surg 2016;16(3):70-8. https://doi.org/10.16956/kjes.2016.16.3.70
- Eismontas V, Slepavicius A, Janusonis V, Zeromskas P, Beisa V, Strupas K, et al. Predictors of postoperative hypocalcemia occurring after a total thyroidectomy: results of prospective multicenter study. BMC Surg 2018;18(1):55. https://doi.org/10.1186/s12893-018-0387-2
- Roh JL, Park JY, Park CI. Prevention of postoperative hypocalcemia with routine oral calcium and vitamin D supplements in patients with differentiated papillary thyroid carcinoma undergoing total thyroidectomy plus central neck dissection. Cancer 2009;115(2):251-8. https://doi.org/10.1002/cncr.24027
- Bellini E, Pia A, Brizzi MP, Tampellini M, Torta M, Terzolo M, et al. Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. Ann Oncol 2011;22(4):988-90.
- Mir O, Coriat R, Boudou-Rouquette P, Durand JP, Goldwasser F. Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications. Ann Oncol 2012;23(1):280-1. https://doi.org/10.1093/annonc/mdr525
- Phillip V, Zahel T, Bartl K, Rasch S, Ebert O, Schmid RM, et al. Influence of Sorafenib and Bevacizumab on pancreatic volume - A monocentric CT based analysis. Pancreatology 2016;16(4):621-4. https://doi.org/10.1016/j.pan.2016.02.010
- Porta C, Cosmai L, Gallieni M, Pedrazzoli P, Malberti F. Renal effects of targeted anticancer therapies. Nat Rev Nephrol 2015;11(6):354-70. https://doi.org/10.1038/nrneph.2015.15
- Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21(8):1637-47. https://doi.org/10.1200/JCO.2003.11.143
- Worden F, Fassnacht M, Shi Y, Hadjieva T, Bonichon F, Gao M, et al. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. Endocr Relat Cancer 2015;22(6):877-87. https://doi.org/10.1530/ERC-15-0252
- Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007;17(4):351-5. https://doi.org/10.1089/thy.2006.0308
- Abdulrahman RM, Verloop H, Hoftijzer H, Verburg E, Hovens GC, Corssmit EP, et al. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab 2010;95(8):3758-62. https://doi.org/10.1210/jc.2009-2507
- Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290(2):H560-76. https://doi.org/10.1152/ajpheart.00133.2005
- Jean GW, Mani RM, Jaffry A, Khan SA. Toxic effects of sorafenib in patients with differentiated thyroid carcinoma compared with other cancers. JAMA Oncol 2016;2(4):529-34. https://doi.org/10.1001/jamaoncol.2015.5927
- Verloop H, Smit JW, Dekkers OM. Sorafenib therapy decreases the clearance of thyrotropin. Eur J Endocrinol 2013;168(2):163-7. https://doi.org/10.1530/EJE-12-0828
- Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 2011;117(3):534-44. https://doi.org/10.1002/cncr.25422